Mirabegron

Active ingredient: Mirabegron

In short: Mirabegron Monotherapy Mirabegron is indicated for the treatment of OAB in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. Mirabegron Mirabegron is indicated for the treatment of NDO in pediatric patients aged 3 years and older and weighing 35 kg or more.

Forms & strengthsMirabegron extended-release tablets are supplied in two different strengths as described below: 25 mg brown, oval, biconvex, bevel edged, film-coated tablets, debossed with "25" on one side and "M" on other side. …
LabelAvKARE
Label updatedNov 02, 2026

What is Mirabegron used for?

Mirabegron

Monotherapy

Mirabegron is indicated for the treatment of OAB in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Mirabegron

Mirabegron is indicated for the treatment of NDO in pediatric patients aged 3 years and older and weighing 35 kg or more.

Mirabegron dosage

Mirabegron extended-release tablets and MYRBETRIQ Granules are two different products, and they are not substitutable on a milligram-per-milligram basis:

Select the recommended product (mirabegron extended-release tablets or MYRBETRIQ Granules) based on the indication and patient’s weight

[see

Indications and Usage (1)

and

Dosage and Administration (2.2,

2.3,

2.4,

2.5)].

Do not combine mirabegron extended-release tablets and MYRBETRIQ Granulesto achieve the total dose.

Mirabegron

Monotherapy

The recommended starting dosage of mirabegron is 25 mg orally once daily. If needed, increase to the maximum dosage of mirabegron 50 mg orally once daily after 4 to 8 weeks. For administration instructions,

see

Dosage and Administration (2.7)

.

For pediatric patients 3 years of age and older, select the appropriate product (mirabegron or MYRBETRIQ Granules) based on the patient’s weight.

Pediatric Patients weighing 35 kg or more: Use Mirabegron

The recommended starting dosage of mirabegron is 25 mg orally once daily. If needed, increase to a maximum dosage of mirabegron 50 mg orally once daily after 4 to 8 weeks. For administration instructions,

see

Dosage and Administration (2.7)

.

Dosage in Adults with Renal Impairment

The recommended dosage of mirabegron (administered orally once daily) in adult patients with renal impairment is described in Table 2

.

For administration instructions,

see

Dosage and Administration (2.7).

Table 2:

Mirabegron

Recommended Dosage in Adult Patients with Renal Impairment (Administered Orally Once Daily)

Estimated GFR

1 | Starting Dose | Maximum Dose

eGFR 30 to 89 mL/min/1.73 m

2 | 25 mg | 50 mg

eGFR 15 to 29 mL/min/1.73 m

2 | 25 mg | 25 mg

eGFR < 15 mL/min/1.73 m

2or requiring dialysis | Not recommended

1. Estimated GFR using the modification of diet in renal disease (MDRD) formula

Dosage in Adults with Hepatic Impairment

The recommended dosage of mirabegron (administered orally once daily) in adult patients with hepatic impairment is described in Table 3

.

For administration instructions,

see

Dosage and Administration (2.7).

Table 3:

Mirabegron

Recommended Dosage in Adult Patients with Hepatic Impairment (Administered Orally Once Daily)

Hepatic Impairment Classification | Starting Dose | Maximum Dose

Child-Pugh Class A (Mild hepatic impairment) | 25 mg | 50 mg

Child-Pugh Class B (Moderate hepatic impairment) | 25 mg | 25 mg

Child-Pugh Class C (Severe hepatic impairment) | Not Recommended

For pediatric patients 3 years of age and older, select the appropriate product (mirabegron) based on the patient’s weight. …

How to take Mirabegron — instructions & advice from the label

Advise the patient and/or caregiver to read the FDA-approved patient labeling (

Patient Information).

Increases in Blood Pressure

Inform patients and/or their caregivers that mirabegron may increase blood pressure. Advise patients, especially patients with hypertension, to periodically monitor their blood pressure and report increased measurement to their health care provider

.

Urinary Retention

Inform patients and/or their caregivers that mirabegron may cause urinary retention in adult patients with bladder outlet obstruction and in patients taking muscarinic antagonist medications for the treatment of OAB. Advise patients to contact their physician if they experience these effects while taking mirabegron

.

Angioedema

Inform patients and/or their caregivers that mirabegron may cause angioedema. Advise patients and/or their caregivers to promptly discontinue mirabegron and seek medical attention if angioedema associated with the upper airway swelling occurs as this may be life-threatening

. …

Warnings & precautions

Do not take this medicine if: Mirabegron is contraindicated in patients with known hypersensitivity reactions to mirabegron or any inactive ingredients of the tablet

.

Increases in Blood Pressure in Adults

Mirabegron can increase blood pressure. Periodic blood pressure determinations are recommended, especially in hypertensive patients. Mirabegron is not recommended for use in patients with severe uncontrolled hypertension (defined as systolic blood pressure greater than or equal to 180 mm Hg and/or diastolic blood pressure greater than or equal to 110 mm Hg)

.

In two, randomized, placebo-controlled, healthy adult volunteer studies, mirabegron was associated with dose-related increases in supine blood pressure. In these studies, at the maximum recommended dose of 50 mg, the mean maximum increase in systolic/diastolic blood pressure was approximately 3.5/1.5 mm Hg greater than placebo.

In contrast, in adult OAB patients in clinical trials, mirabegron, taken as monotherapy, the mean increase in systolic and diastolic blood pressure at the maximum recommended mirabegron dose of 50 mg was approximately 0.5 to 1 mm Hg greater than placebo. Worsening of pre-existing hypertension was reported infrequently in patients taking mirabegron.

Increases in Blood Pressure in Pediatric Patients 3 Years and Older

Mirabegron can increase blood pressure in pediatric patients. Blood pressure increases may be larger in children (3 to less than 12 years of age) than in adolescents (12 to less than 18 years of age). Periodic blood pressure determinations are recommended. Mirabegron is not recommended for use in pediatric patients with severe uncontrolled hypertension, defined as a systolic and/or diastolic blood pressure above the 99th percentile plus 5 mm Hg for age, sex, and stature using appropriate reference values

. …

Mirabegron side effects

The following adverse reactions are discussed in more detail in other sections of the labeling.

Hypertension

Urinary Retention

Angioedema

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Mirabegron

Monotherapy for Adult OAB

In three, 12-week, double-blind, placebo-controlled, safety and efficacy studies in patients with OAB (Studies 1, 2, and 3), mirabegron was evaluated for safety in 2736 patients

. Study 1 also included an active control. For the combined Studies 1, 2, and 3, 432 patients received mirabegron 25 mg, 1,375 received mirabegron 50 mg, and 929 received mirabegron 100 mg once daily. In these studies, the majority of the patients were Caucasian (94%) and female (72%) with a mean age of 59 years (range 18 to 95 years).

Mirabegron was also evaluated for safety in 1632 patients who received mirabegron 50 mg once daily (n=812 patients) or mirabegron 100 mg (n=820 patients) in a 1-year, randomized, fixed-dose, double-blind, active-controlled, safety study in patients with OAB (Study 4). Of these patients, 731 received mirabegron in a previous 12-week study. …

Drug interactions

Drug interaction studies were conducted in adult patients to investigate the effect of co-administered drugs on the pharmacokinetics of mirabegron and the effect of mirabegron on the pharmacokinetics of co-administered drugs (e.g., ketoconazole, rifampin, solifenacin succinate, tamsulosin, and oral contraceptives)

. No dose adjustment is recommended when these drugs are co-administered with mirabegron.

The following are drug interactions for which monitoring is recommended:

Since mirabegron is a moderate CYP2D6 inhibitor, the systemic exposure of drugs metabolized by CYP2D6 enzyme is increased when co-administered with mirabegron. Therefore, appropriate monitoring and dose adjustment may be necessary when mirabegron is co-administered with these drugs, especially with narrow therapeutic index CYP2D6 substrates

.

When given in combination, 100 mg mirabegron increased mean digoxin C

maxfrom 1.01 to 1.3 ng/mL (29%) and AUC from 16.7 to 19.3 ng.h/mL (27%). For patients who are initiating a combination of mirabegron and digoxin, the lowest dose for digoxin should initially be considered. Serum digoxin concentrations should be monitored and used for titration of the digoxin dose to obtain the desired clinical effect

. …

About this medicine

Mirabegron extended-release tablets for oral use and are beta-3 adrenergic agonists.

The chemical name of mirabegron is 2-(2-aminothiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide having a molecular formula of C

21H

24N

4O

2S and a molecular weight of 396.51. The structural formula of mirabegron is:

Mirabegron is a white to yellowish color powder. It is practically insoluble in water (0.082 mg/mL). It is soluble in methanol and dimethyl sulfoxide.

Each mirabegron extended-release tablet for oral use contains either 25 mg or 50 mg of mirabegron and the following inactive ingredients: hydroxypropyl cellulose, hypromellose, iron oxide red, iron oxide yellow, magnesium stearate, polyethylene glycol, polyethylene oxide, and titanium dioxide.

How it works: Mirabegron is an agonist of the human beta-3 adrenergic receptor (AR) as demonstrated by in vitrolaboratory experiments using the cloned human beta-3 AR. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 5f102149-ad27-4956-e063-6294a90ac6ad. Read the full official label on DailyMed.